| P50 | author | Stephan Stilgenbauer | Q47158807 |
| P2093 | author name string | Henriette Huber | |
| | Sven Estenfelder | |
| | Simone Edenhofer | |
| P2860 | cites work | The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 |
| | Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential | Q26747753 |
| | Targeted therapies in CLL: mechanisms of resistance and strategies for management | Q27002528 |
| | ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Q27683708 |
| | Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib | Q27853011 |
| | Genomic aberrations and survival in chronic lymphocytic leukemia | Q28141442 |
| | The BCL-2 protein family: opposing activities that mediate cell death | Q29547380 |
| | Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity | Q33392920 |
| | Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group | Q33396737 |
| | Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease | Q33398808 |
| | Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial | Q33412064 |
| | MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies | Q33419789 |
| | Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. | Q33421292 |
| | Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study | Q33432228 |
| | Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. | Q33794311 |
| | Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies | Q33893704 |
| | Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia | Q34009003 |
| | Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia | Q34052075 |
| | Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial | Q34141305 |
| | Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. | Q54316160 |
| | Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. | Q54328623 |
| | Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions | Q56657194 |
| | Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells | Q56901814 |
| | Involvement of the bcl-2 gene in human follicular lymphoma | Q69870224 |
| | Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques | Q73423141 |
| | Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells | Q79420945 |
| | Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial | Q83441006 |
| | VSV Oncolysis in Combination With the BCL-2 Inhibitor Obatoclax Overcomes Apoptosis Resistance in Chronic Lymphocytic Leukemia | Q34382986 |
| | Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia | Q34504188 |
| | Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab) | Q34508322 |
| | Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib | Q35450520 |
| | Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes | Q35625192 |
| | Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia | Q35903984 |
| | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 |
| | A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiency | Q36358469 |
| | Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia | Q36490049 |
| | Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia | Q36597026 |
| | Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo | Q36619787 |
| | Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia | Q36888218 |
| | Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. | Q37097096 |
| | High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells | Q37209768 |
| | Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes | Q37226729 |
| | Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies | Q38142762 |
| | Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial | Q38424831 |
| | Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. | Q38563530 |
| | Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib | Q38721654 |
| | Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination? | Q38850312 |
| | Venetoclax: First Global Approval | Q38853500 |
| | Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. | Q38959765 |
| | Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. | Q38999783 |
| | Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial | Q39005118 |
| | BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma | Q40357519 |
| | State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia | Q40786236 |
| | Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib | Q41601558 |
| | The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein | Q42383180 |
| | Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. | Q43145571 |
| | Comorbidity and functional status are independent in older cancer patients | Q44747457 |
| | Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia | Q46247309 |
| | Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia | Q46378902 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lymphocyte | Q715347 |
| P304 | page(s) | 645-656 | |
| P577 | publication date | 2017-02-07 | |
| P1433 | published in | OncoTargets and Therapy | Q7092081 |
| P1476 | title | Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia | |
| P478 | volume | 10 | |